-
Tytuł:
-
CD39 T cells mediate metastatic dormancy in breast cancer.
-
Autorzy:
-
Tallón de Lara P; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.; Department of Medicine, Mount Sinai St. Luke's & Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Castañón H; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Vermeer M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Núñez N; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Sobottka B; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Urdinez J; Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.; Cutiss AG, Schlieren, Switzerland.
Cecconi V; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Yagita H; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Movahedian Attar F; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Hiltbrunner S; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.; Department of Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland.
Glarner I; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Moch H; Comprehensive Cancer Center Zurich, Zurich, Switzerland.; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Tugues S; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
Becher B; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.
van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. .; Comprehensive Cancer Center Zurich, Zurich, Switzerland. .
-
Źródło:
-
Nature communications [Nat Commun] 2021 Feb 03; Vol. 12 (1), pp. 769. Date of Electronic Publication: 2021 Feb 03.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [London] : Nature Pub. Group
-
MeSH Terms:
-
Antigens, CD/*immunology
Apyrase/*immunology
Breast Neoplasms/*immunology
CD8-Positive T-Lymphocytes/*immunology
Mammary Neoplasms, Experimental/*immunology
Programmed Cell Death 1 Receptor/*immunology
Animals ; Antigens, CD/metabolism ; Apyrase/metabolism ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; CD8-Positive T-Lymphocytes/metabolism ; Cell Line, Tumor ; Humans ; Immunotherapy ; Lung/immunology ; Lung/pathology ; Mammary Neoplasms, Experimental/pathology ; Mammary Neoplasms, Experimental/therapy ; Mice, Inbred BALB C ; Mice, Inbred NOD ; Mice, Knockout ; Neoplasm Metastasis ; Programmed Cell Death 1 Receptor/metabolism ; Mice
-
References:
-
Nat Protoc. 2014 Jan;9(1):171-81. (PMID: 24385147)
Nat Commun. 2017 Apr 06;8:14825. (PMID: 28382969)
JCI Insight. 2019 Oct 3;4(19):. (PMID: 31465302)
Nat Protoc. 2019 Feb;14(2):482-517. (PMID: 30664679)
J Pathol. 2012 Jun;227(2):234-44. (PMID: 22262199)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Nature. 2015 Dec 17;528(7582):413-7. (PMID: 26649828)
Science. 2018 Sep 28;361(6409):. (PMID: 30262472)
Nature. 2018 May;557(7706):575-579. (PMID: 29769722)
Nature. 2019 Jul;571(7764):270-274. (PMID: 31207604)
Methods Mol Biol. 2018;1845:71-86. (PMID: 30141008)
Nat Rev Cancer. 2007 Nov;7(11):834-46. (PMID: 17957189)
Clin Cancer Res. 2011 May 1;17(9):2967-76. (PMID: 21415211)
Nature. 2007 Dec 6;450(7171):903-7. (PMID: 18026089)
Annu Rev Immunol. 2019 Apr 26;37:457-495. (PMID: 30676822)
Nat Rev Cancer. 2015 Apr;15(4):238-47. (PMID: 25801619)
Nat Med. 2018 Jul;24(7):986-993. (PMID: 29942092)
Cell. 2016 Mar 24;165(1):45-60. (PMID: 27015306)
Cancer Res. 2013 Mar 15;73(6):1721-32. (PMID: 23345161)
Cell Signal. 2013 Apr;25(4):961-9. (PMID: 23333246)
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55. (PMID: 21081700)
Nat Cell Biol. 2017 Aug;19(8):974-987. (PMID: 28737771)
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2. (PMID: 18432775)
Ann Oncol. 2014 Aug;25(8):1536-43. (PMID: 24915873)
J Exp Med. 2019 Sep 2;216(9):2128-2149. (PMID: 31227543)
N Engl J Med. 2005 Aug 25;353(8):793-802. (PMID: 16120859)
Nat Commun. 2018 Jul 13;9(1):2724. (PMID: 30006565)
Cancer Discov. 2019 Dec;9(12):1754-1773. (PMID: 31699796)
Nat Cell Biol. 2013 Nov;15(11):1351-61. (PMID: 24161934)
Cytometry A. 2016 Dec;89(12):1084-1096. (PMID: 27992111)
Nat Med. 2018 Feb;24(2):144-153. (PMID: 29309059)
J Clin Invest. 2010 Jun;120(6):2030-9. (PMID: 20501944)
BMC Bioinformatics. 2016 Jun 02;17(1):228. (PMID: 27255077)
Nat Biotechnol. 2013 Jun;31(6):539-44. (PMID: 23609047)
Immunol Rev. 2018 May;283(1):161-175. (PMID: 29664565)
J Immunol. 2015 Jun 1;194(11):5529-38. (PMID: 25911761)
Cancer Immunol Res. 2020 Mar;8(3):356-367. (PMID: 31992567)
N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
Nat Commun. 2018 Oct 16;9(1):4297. (PMID: 30327458)
Cancer Discov. 2017 Feb;7(2):177-187. (PMID: 27974414)
J Clin Oncol. 2010 Jul 10;28(20):3271-7. (PMID: 20498394)
Nat Cell Biol. 2019 Feb;21(2):238-250. (PMID: 30664790)
Cytometry A. 2015 Jul;87(7):636-45. (PMID: 25573116)
J Immunol. 2007 Feb 15;178(4):2132-40. (PMID: 17277117)
Cell. 1994 Oct 21;79(2):315-28. (PMID: 7525077)
Cancer Discov. 2016 Jun;6(6):630-49. (PMID: 27072748)
Sci Immunol. 2017 Jan 6;2(7):. (PMID: 28783666)
Nat Protoc. 2019 Jul;14(7):1946-1969. (PMID: 31160786)
Nat Commun. 2019 Jun 3;10(1):2387. (PMID: 31160572)
Immunity. 2016 May 17;44(5):989-1004. (PMID: 27192565)
Breast Cancer Res Treat. 1996;41(2):177-85. (PMID: 8944336)
J Immunol. 2004 May 1;172(9):5450-5. (PMID: 15100286)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Br J Cancer. 2014 Mar 4;110(5):1378-84. (PMID: 24434426)
Science. 2018 Jun 15;360(6394):. (PMID: 29773669)
Cell. 2019 May 16;177(5):1330-1345.e18. (PMID: 30982598)
Nat Rev Immunol. 2019 Nov;19(11):665-674. (PMID: 31570879)
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21704-21714. (PMID: 31591235)
Nat Cell Biol. 2018 Nov;20(11):1240-1249. (PMID: 30361702)
Nat Cell Biol. 2013 Jul;15(7):807-17. (PMID: 23728425)
JCI Insight. 2018 May 17;3(10):. (PMID: 29769439)
Nat Rev Cancer. 2014 Sep;14(9):611-22. (PMID: 25118602)
Cancer Res. 1992 Mar 15;52(6):1399-405. (PMID: 1540948)
Cancer Res. 2018 Jan 1;78(1):115-128. (PMID: 29066514)
Nature. 2019 Mar;567(7749):540-544. (PMID: 30867597)
Nat Commun. 2019 Sep 27;10(1):4401. (PMID: 31562311)
Cancer Res. 2006 Feb 1;66(3):1702-11. (PMID: 16452230)
Nat Rev Cancer. 2017 May;17(5):302-317. (PMID: 28303905)
Nature. 2013 Feb 21;494(7437):361-5. (PMID: 23376950)
Cell Rep. 2017 Apr 25;19(4):774-784. (PMID: 28445728)
Cell. 2017 Jan 26;168(3):487-502.e15. (PMID: 28111070)
Nat Med. 2015 Jul;21(7):688-97. (PMID: 26121195)
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16885-90. (PMID: 15548615)
Nat Commun. 2017 Apr 06;8:14979. (PMID: 28382931)
J Natl Cancer Inst. 1999 Jan 6;91(1):80-5. (PMID: 9890174)
Nat Cell Biol. 2015 Jun;17(6):816-26. (PMID: 25985394)
-
Substance Nomenclature:
-
0 (Antigens, CD)
0 (Programmed Cell Death 1 Receptor)
EC 3.6.1.5 (Apyrase)
EC 3.6.1.5 (CD39 antigen)
-
Entry Date(s):
-
Date Created: 20210204 Date Completed: 20210222 Latest Revision: 20240330
-
Update Code:
-
20240330
-
PubMed Central ID:
-
PMC7859213
-
DOI:
-
10.1038/s41467-021-21045-2
-
PMID:
-
33536445
-
Some breast tumors metastasize aggressively whereas others remain dormant for years. The mechanism governing metastatic dormancy remains largely unknown. Through high-parametric single-cell mapping in mice, we identify a discrete population of CD39 + PD-1 + CD8 + T cells in primary tumors and in dormant metastasis, which is hardly found in aggressively metastasizing tumors. Using blocking antibodies, we find that dormancy depends on TNFα and IFNγ. Immunotherapy reduces the number of dormant cancer cells in the lungs. Adoptive transfer of purified CD39 + PD-1 + CD8 + T cells prevents metastatic outgrowth. In human breast cancer, the frequency of CD39 + PD-1 + CD8 + but not total CD8 + T cells correlates with delayed metastatic relapse after resection (disease-free survival), thus underlining the biological relevance of CD39 + PD-1 + CD8 + T cells for controlling experimental and human breast cancer. Thus, we suggest that a primary breast tumor could prime a systemic, CD39 + PD-1 + CD8 + T cell response that favors metastatic dormancy in the lungs.